Managing early latent syphilis — infection acquired within the past year — requires careful attention when the patient also has a bleeding disorder. The coexisting bleeding disorder has direct clinical relevance to the selection of the treatment approach.

Clinical Scenario

Early latent syphilis is classified as infection acquired within the first year. In this scenario, the patient additionally has a bleeding disorder, a comorbidity that meaningfully influences how treatment is administered.

Treatment Approach

Antibiotic therapy is indicated. The protocol defines both a primary regimen and an oral alternative — and the choice between them is directly shaped by the patient's bleeding disorder.

Complete agent selection, dosing, duration, and the full clinical decision pathway are in the structured protocol →

Treatment Goal

Following treatment, serological response should be monitored: a non-treponemal antibody titre (VDRL/RPR) drawn at day 0 is expected to fall by a fourfold decrease or more within 6 months.

References

Rather arbitrarily classified as early if within the first year of infection and late (or undetermined duration) after ≥1 year.
Bleeding disorders
Ceftriaxone 1g intravenously (IV) in a single daily dose for 10 days
Doxycycline 200 mg daily (either 100 mg twice daily or as a single 200 mg dose) orally for 14 days
After treatment of early syphilis, the titre of a NTT taken at day 0 (e.g. VDRL and/or RPR) should decline by ≥2 dilution steps (≥fourfold decrease in titre of antibodies) within 6 months.

DOI: 10.1111/jdv.16946

View source ↗

Treatment of Early Latent Syphilis in Patients with a Bleeding Disorder

Clinical Scenario

Treatment Approach

Treatment Goal

References